- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Health Care Businesses
Head of Lilly's oncology unit resigning
January 25, 2011
John H. Johnson has been hired as CEO by East Brunswick, N.J.-based biotechnology company Savient Pharmaceuticals Inc.
MoreVanderbilt rejected by high court on Cialis patents
January 24, 2011
Bloomberg NewsSupreme Court justices on Monday left intact a ruling throwing out a lawsuit pressed by the Nashville, Tenn., university against
Eli Lilly's Icos subsidiary.
MoreLilly seeks to block imports of cancer drug copy
January 21, 2011
Bloomberg NewsThe local drugmaker told the International Trade Commission on Thursday that the generic version of Gemzar violates its patent
on the process for making the active ingredient.
MoreLilly imaging drug fails to win FDA panel's backing
January 21, 2011
Bloomberg NewsEli Lilly and Co.'s Amyvid isn't ready to be approved to detect Alzheimer's-related deposits in the brain, according to FDA
advisors. The medicine could still be approved if Lilly establishes a training program and a way to ensure that the results
of brain scans are read consistently, they said.
MoreCarmel firm gets FDA approval for lice treatment
January 18, 2011
IBJ StaffParaPRO LLC's treatment, called Natroba, has a potential U.S. market of 6 million to 12 million infected children annually.
MoreLilly imaging drug isn't ready for approval, FDA says
January 18, 2011
Eli Lilly and Co.’s experimental drug to help identify plaque in the brain tied to Alzheimer's disease isn't ready for approval,
according to U.S. regulators.
MoreRoche back in court as partner looks to sell to competitor
January 12, 2011
J.K. WallRoche Diagnostics requested a temporary restraining order against Medical Automation Systems Inc. Tuesday after receiving
word the company is speeding up plans to sell itself to Roche rival Alere Inc.
MoreClosed dental company working to transfer patients
January 10, 2011
Associated PressCiting cash-flow problems, Allcare Dental and Dentures shut down operations in 14 states, including Indiana, last week.
MoreLilly's Solpura may lack data to prove effectiveness
January 10, 2011
Bloomberg NewsOutside advisers to the FDA will meet Jan. 12 to review whether the drug should be approved for people with pancreas insufficiency
caused by cystic fibrosis, chronic pancreatitis or other conditions.
MoreLilly bumped up federal lobbying in third quarter
January 4, 2011
Associated PressThe Indianapolis-based drugmaker spent $2.1 million in the three months that ended Sept. 30, a 5-percent increase from the
same quarter last year and a jump of more than 30 percent from the $1.6 million it spent in this year's second quarter.
MoreLilly, other big drugmakers shut out by FDA in 2010
January 3, 2011
IBJ Staff and Bloomberg NewsRegulators cleared 21 medicines, the fewest since 2007, for sale last year. It was the first time in a decade that Pfizer
Inc., the world's largest drugmaker, as well as Lilly, Merck & Co. and Bristol-Myers Squibb Co. were shut out at the same
time, according to agency records.
MoreRoche acquires Marcadia Biotech
December 30, 2010
Chris O'MalleyMarcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by prominent scientists from Eli Lilly and Co. in
2006, has been acquired by Swiss life sciences giant Roche.
MoreLilly suspends late-stage trial for melanoma drug
December 13, 2010
Bloomberg NewsEli Lilly and Co. suspended a late-stage clinical trial of a medicine for skin-cancer patients after 12 patients in the study
died.
MoreNursing home firm to pay $376K in Medicaid case
December 6, 2010
Associated PressIndiana Attorney General Greg Zoeller says a nursing home company will pay $376,000 to the state and federal governments over
accusations that it submitted ineligible bills to Medicaid.
MoreSt. Francis-WellPoint deal is a sign of the times
November 27, 2010
J.K. WallSt. Francis, which operates three Indianapolis-area hospitals, and WellPoint, the giant health insurer, announced this month
that they have agreed to jointly form an accountable care organization.
MoreLilly, Acrux receive FDA approval for Axiron
November 24, 2010
IBJ Staff and Bloomberg NewsThe companies believe the underarm testosterone solution has the potential to realize sales of more than $1 billion a year
in the United States.
MoreMedical device maker expanding in Fort Wayne
November 18, 2010
L.H. Medical Corp. said it plans to create up to 65 jobs by 2013 and invest $5.4 million to more than triple the size of its
manufacturing operations.
MoreDrugmakers seek Republican allies to defeat cost-cutting panel
November 15, 2010
Bloomberg NewsPharmaceutical firms led by Eli Lilly are trying to eliminate a government panel aimed at controlling Medicare spending seven
months after they supported the health-care overhaul that created it.
MoreStudy: Arthritis drug co-developed by Lilly shows promise
November 12, 2010
IBJ Staff and Bloomberg NewsLilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications
for autoimmune diseases.
MoreMoody's downgrades long-term ratings for Eli Lilly
November 9, 2010
Associated PressMoody's Investors Service on Monday lowered the long-term ratings of Lilly one notch, to A2 from A1, citing a wave of patent
expirations the drugmaker faces in coming years.
MoreLilly makes $300M deal for Philadelphia drug company
November 8, 2010
J.K. WallEli Lilly said it will acquire Avid Radiopharmaceuticals, maker of an experimental agent that could help identify patients
with Alzheimer's disease. The price could climb to $800 million if the agent is commercially successful.
MoreAppeals court rejects Lilly over Gemzar patent
November 1, 2010
IBJ Staff and Bloomberg NewsWithout an appeal, generic drugs are now poised to wipe away most of Lilly's $750 million in annual U.S. revenue from Gemzar.
MoreIndiana's life sciences industry sees trouble ahead
October 30, 2010
Associated PressIndiana's life sciences industry has weathered the recession relatively well, but Eli Lilly's struggles and tight capital
markets could threaten the future.
MoreAnalysts: Lilly setbacks might spur shopping spree
October 22, 2010
Bloomberg NewsCEO John Lechleiter claims Eli Lilly and Co. isn't interested in big acquisitions to bolster its flagging drug pipeline, but
its recently devalued partner Amylin Pharmaceuticals might be the right fit, industry analysts say.
MoreUPDATE: Lilly, others see stock slide after drug rejection
October 20, 2010
Bloomberg NewsStock in Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. dropped after they were rebuffed a second time in
a bid to gain U.S. approval of a once-weekly version of the diabetes drug Byetta.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Can IBJ please stop referring to this property as "Kessler Mansion"? What a ridiculous title for the biggest, bloated, blight in our city. It's not a mansion. At best, it's an ideal site to shoot low-budget porn. Ahhh! Another business use!
Its stories like these that prove that a Ball State diploma is worth less than the paper that its printed on. A real institution of higher learning would have taken care of this long ago. No way should this crap be taught in a SCIENCE class.
It is such a shame that King Ballard has made Indianapolis into Chicago south with all of the rampant corruption.
How many of these 1,259 bills were actually heard and voted on on the floor vs how many were shot down in committee?
When a an arrogant young guy with essentially no experience and no qualifications for the job, was dropped into an Administrator position out of nowhere by his "mentor" in the Mayor's office things seemed fishy. Sometimes things are what they seem.